Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
Read our latest update

US Bioservices now dispenses LENVIMA® (lenvatinib)

September 17, 2020

LENVIMA® (lenvatinib) is a kinase inhibitor indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC) and in combination with everolimus to treat patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). It is also indicated in combination with pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.